| Uso de fármacos serotoninérgicos para tratar la obesidad. ¿Existe alguna esperanza? |
The use of serotonergic drugs to treat obesity--is there any hope?
Bello NT, Liang NC.
Department of Animal Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ 08901, USA. ntbello@rci.rutgers.edu
Drug Des Devel Ther. 2011 Feb 10;5:95-109.
Abstract
Surgical interventional strategies for the treatment of obesity are being implemented at an increasing rate. The safety and feasibility of these procedures are questionable for most overweight or obese individuals. The use of long-term pharmacotherapy options, on the other hand, can target a greater portion of the obese population and provide early intervention to help individuals maintain a healthy lifestyle to promote weight loss. Medications that act on the central serotonergic pathways have been a relative mainstay for the treatment of obesity for the last 35 years. The clinical efficacy of these drugs, however, has been encumbered by the potential for drug-associated complications. Two drugs that act, albeit by different mechanisms, on the central serotonergic system to reduce food intake and decrease body weight are sibutramine and lorcaserin. Sibutramine is a serotonin and norepinephrine reuptake inhibitor, whereas lorcaserin is a selective 5HT(2C) receptor agonist. The recent worldwide withdrawal of sibutramine and FDA rejection of lorcaserin has changed the landscape not only for serotonin-based therapeutics specifically, but for obesity pharmacotherapy in general. The purpose of this review is to focus on the importance of the serotonergic system in the control of feeding and its potential as a target for obesity pharmacotherapy. Advances in refining and screening more selective receptor agonists and a better understanding of the potential off-target effects of serotonergic drugs are needed to produce beneficial pharmacotherapy.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063114/pdf/dddt-5-095.pdf
|
| Uso de lorcaserin en el tratamiento de la obesidad: evaluación crítica |
The use of lorcaserin in the management of obesity: a critical appraisal.
Bai B, Wang Y.
Department of Pharmacology and Pharmacy, University of Hong Kong, People's Republic of China.
Drug Des Devel Ther. 2010 Dec 20;5:1-7.
Abstract
Obesity is a chronic disease with a high prevalence in both developed and developing countries. Effective management of this worldwide epidemic will have a significant impact on the health care system globally. Lifestyle interventions, such as restricting calorie consumption and increasing physical activity, remain a major component of weight-reduction programs. The development of pharmacotherapy for the management of obesity is still at the infancy stage. Side effects have been the key issue for anti-obesity drugs previously withdrawn from the market. The focus of this review, lorcaserin, is a selective serotonin receptor agonist that is currently undergoing Phase III evaluations. The efficacy of this drug in reducing body weight and improving metabolic parameters of obese patients has been demonstrated in two recent clinical trials. The available evidence indicates that this drug does not show unwanted effects on heart valves or pulmonary artery pressure, and the treatment improves the risk factors for type 2 diabetes and cardiovascular diseases. Despite these promising results, additional experimental and clinical studies are critical for the approval of lorcaserin as a new anti-obesity monodrug therapy by the US Food and Drug Administration.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3023275/?tool=pubmed
|
|
No hay comentarios:
Publicar un comentario